Validation of a prostate cancer polygenic risk score. 2020

Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
Ambry Genetics, Aliso Viejo, California.

Genome-wide association studies have identified over 100 single-nucleotide polymorphisms (SNPs) associated with prostate cancer (PrCa), and polygenic risk scores (PRS) based on their combined genotypes have been developed for risk stratification. We aimed to assess the contribution of PRS to PrCa risk in a large multisite study. The sample included 1972 PrCa cases and 1919 unaffected controls. Next-generation sequencing was used to assess pathogenic variants in 14 PrCa-susceptibility genes and 72 validated PrCa-associated SNPs. We constructed a population-standardized PRS and tested its association with PrCa using logistic regression adjusted for age and family history of PrCa. The mean age of PrCa cases at diagnosis and age of controls at testing/last clinic visit was 59.5 ± 7.2 and 57.2 ± 13.0 years, respectively. Among 1740 cases with pathology data, 57.4% had Gleason score ≤ 6, while 42.6% had Gleason score ≥ 8. In addition, 39.6% cases and 20.1% controls had a family history of PrCa. The PRS was significantly higher in cases than controls (mean ± SD: 1.42 ± 1.11 vs 1.02 ± 0.76; P < .0001). Compared with men in the 1st quartile of age-adjusted PRS, those in the 2nd, 3rd, and 4th quartile were 1.58 (95% confidence interval [CI]: 1.31-1.90), 2.36 (95% CI: 1.96-2.84), and 3.98 (95% CI: 3.29-4.82) times as likely to have PrCa (all P < .0001). Adjustment for family history yielded similar results. PRS predictive performance was consistent with prior literature (area under the receiver operating curve = 0.64; 95% CI: 0.62-0.66). These data suggest that a 72-SNP PRS is predictive of PrCa, supporting its potential use in clinical risk assessment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D055106 Genome-Wide Association Study An analysis comparing the allele frequencies of all available (or a whole GENOME representative set of) polymorphic markers to identify gene candidates or quantitative trait loci associated with a specific organism trait or specific disease or condition. Genome Wide Association Analysis,Genome Wide Association Study,GWA Study,Genome Wide Association Scan,Genome Wide Association Studies,Whole Genome Association Analysis,Whole Genome Association Study,Association Studies, Genome-Wide,Association Study, Genome-Wide,GWA Studies,Genome-Wide Association Studies,Studies, GWA,Studies, Genome-Wide Association,Study, GWA,Study, Genome-Wide Association
D059014 High-Throughput Nucleotide Sequencing Techniques of nucleotide sequence analysis that increase the range, complexity, sensitivity, and accuracy of results by greatly increasing the scale of operations and thus the number of nucleotides, and the number of copies of each nucleotide sequenced. The sequencing may be done by analysis of the synthesis or ligation products, hybridization to preexisting sequences, etc. High-Throughput Sequencing,Illumina Sequencing,Ion Proton Sequencing,Ion Torrent Sequencing,Next-Generation Sequencing,Deep Sequencing,High-Throughput DNA Sequencing,High-Throughput RNA Sequencing,Massively-Parallel Sequencing,Pyrosequencing,DNA Sequencing, High-Throughput,High Throughput DNA Sequencing,High Throughput Nucleotide Sequencing,High Throughput RNA Sequencing,High Throughput Sequencing,Massively Parallel Sequencing,Next Generation Sequencing,Nucleotide Sequencing, High-Throughput,RNA Sequencing, High-Throughput,Sequencing, Deep,Sequencing, High-Throughput,Sequencing, High-Throughput DNA,Sequencing, High-Throughput Nucleotide,Sequencing, High-Throughput RNA,Sequencing, Illumina,Sequencing, Ion Proton,Sequencing, Ion Torrent,Sequencing, Massively-Parallel,Sequencing, Next-Generation

Related Publications

Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
September 2022, Current opinion in urology,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
October 2020, Scientific reports,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
April 2023, JAMA internal medicine,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
April 2022, NPJ precision oncology,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
May 2023, European urology,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
April 2024, Familial cancer,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
May 2022, Journal of the National Cancer Institute,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
March 2019, Translational cancer research,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
September 2015, The Prostate,
Mary H Black, and Shuwei Li, and Holly LaDuca, and Min-Tzu Lo, and Jefferey Chen, and Robert Hoiness, and Stephanie Gutierrez, and Brigette Tippin-Davis, and Hsiao-Mei Lu, and Marta Gielzak, and Kathleen Wiley, and Zhuqing Shi, and Jun Wei, and Siqun Lilly Zheng, and Brian T Helfand, and William Isaacs, and Jianfeng Xu
January 2020, JCO precision oncology,
Copied contents to your clipboard!